Contributing Author
in
Contract Research
Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.
As we approach 2025, the role of chemistry Contract Research Organizations (CROs) is undergoing profound transformation. Chemistry is no longer considered a commodity but an essential component in the discovery of new medicines. Biotech companies are no longer satisfied with "more chemists" or "bigger libraries"; they now demand partners with specialized expertise to tackle the increasing complexity of chemical research, which has become the new norm for small molecules, and even more so for emerging modalities such as bRo5 molecules, PROTACs, antibody-drug conjugates (ADCs), and radiopharmaceuticals. These new modalities call for advanced capabilities in macrocycles, linker design, and bifunctional agents—demanding a redefinition of CRO capabilities.
